Clinical Trial Update: Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 trial update on personalized extended interval dosing of natalizumab for relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 4 | Status: UNKNOWN